• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    TransThera Sciences (Nanjing) (SEHK:2617) Stock Sees Revenue Emerge As Losses Persist

    Simply Wall St·08/27/2026 12:35:14
    Listen to the news

    TransThera Sciences (Nanjing) stock came into this earnings print bruised, with the 90 day return deep in the red despite a small bounce over the past week and month. Yet the latest H1 2026 numbers tell a more nuanced story. Revenue landed at C¥35.455 million, a clear shift for a company that previously reported no sales, while earnings still showed a sizeable loss with basic earnings per share of C¥0.24 in the red. The real question for the market now is whether this early top line traction justifies a still punchy P/B multiple and recent volatility.

    Is TransThera Sciences (Nanjing) stock pricing in potential future growth, or is it simply reflecting volatility and recent losses? Compare its current P/B ratio, revenue forecasts, and loss profile with peers in the valuation analysis for TransThera Sciences (Nanjing).

    H1 2026 Earnings Summary

    • Revenue (H1 2026 vs H1 2025): C¥35.455 million vs. C¥0 million (shift to reported revenue from no revenue)
    • Net Loss (H1 2026 vs H1 2025): C¥95.465 million loss vs. C¥122.866 million loss (narrowed loss)
    • Basic EPS (H1 2026 vs H1 2025): C¥0.24 loss per share vs. C¥0.321461 loss per share (smaller loss per share)
    • Pipeline Progress (Trailing 12 Months to H2 2025): 9 products in Phase I, 4 in Phase II, 1 in Phase III, and 1 in pre-registration (reflecting a broad clinical development portfolio for TransThera Sciences Nanjing)

    Prefer visual charts over scrolling through another wall of numbers and clinical trial details? See TransThera Sciences (Nanjing)'s full financial picture, including an at-a-glance view of its balance sheet strength and cash position, in the interactive company report for TransThera Sciences (Nanjing).

    SEHK:2617 Trailing 12-Month Earnings & Revenue History as at Aug 2026
    SEHK:2617 Trailing 12-Month Earnings & Revenue History as at Aug 2026

    TransThera Sciences bullish signals versus fresh revenue

    For investors leaning optimistic on TransThera Sciences, the first recorded revenue of C¥35.455 million and a narrower net loss of C¥95.465 million help the story. Loss per share also moved closer to breakeven. A broad pipeline that includes products in Phase I through pre registration supports the idea that the business model is progressing from pure research toward a more commercial footing. Recent 7 day and 30 day share price gains, even after a sharp 90 day decline, suggest sentiment is at least stabilising around this shift.

    TransThera Sciences risks around losses and volatility

    The bearish angle for TransThera Sciences still finds support in the numbers. The company remains firmly loss making with C¥95.465 million in losses in H1 2026 and basic EPS of C¥0.24 in the red. Revenue is new and small relative to the loss base, so the business is not yet close to self funding. The 90 day share price decline of 69.9% highlights how sensitive investors remain to execution and funding risk in a clinical stage biotech, even with recent short term price relief.

    Review whether TransThera Sciences volatility and ongoing losses are early warning signs by scanning the independent risk analysis for TransThera Sciences (Nanjing) which shows 2 important warning signs.

    Stay Ahead With Simply Wall St

    If TransThera Sciences (Nanjing)'s first reported revenue and recent share price swings have your attention, register for free with Simply Wall St and add the stock to your Watchlist to track price against fair value and watch how the story develops. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the key updates that matter to your holdings. For longer term context and fresh angles, tap into crowd views and thesis sharing through the Community. By surfacing potential catalysts and risks early, Simply Wall St helps you act with confidence and stay ahead of the market.

    Seeking Alternatives Beyond TransThera Sciences

    Fresh ideas can move fast. Some stocks gain momentum, others get caught dropping, and early entries often set the tone. Scan these under the radar lists before the crowd and act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.